Published in N Engl J Med on September 11, 2003
Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. J Am Coll Cardiol (2010) 2.68
Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation (2011) 2.32
Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol (2011) 1.55
Coronary flow reserve in stress-echo lab. From pathophysiologic toy to diagnostic tool. Cardiovasc Ultrasound (2005) 1.53
Myocardial perfusion reserve in spared myocardium: correlation with infarct size and left ventricular ejection fraction. Eur J Nucl Med Mol Imaging (2013) 1.43
The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2012) 1.32
Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis. J Am Coll Cardiol (2007) 1.29
Coronary microvascular dysfunction: an update. Eur Heart J (2013) 1.28
Coronary microvascular resistance: methods for its quantification in humans. Basic Res Cardiol (2009) 1.26
Management of hypertrophic cardiomyopathy. BMJ (2006) 1.18
In vivo cardiovascular magnetic resonance diffusion tensor imaging shows evidence of abnormal myocardial laminar orientations and mobility in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson (2014) 1.14
Coronary microvascular dysfunction in the clinical setting: from mystery to reality. Eur Heart J (2012) 1.07
Role of PET in the evaluation and understanding of coronary physiology. J Nucl Cardiol (2007) 1.02
Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. Nat Rev Cardiol (2009) 1.01
Assessing risk in hypertrophic cardiomyopathy. N Engl J Med (2003) 1.01
Voxel-wise quantification of myocardial blood flow with cardiovascular magnetic resonance: effect of variations in methodology and validation with positron emission tomography. J Cardiovasc Magn Reson (2014) 1.00
Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc Res (2015) 0.96
Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovasc Ultrasound (2010) 0.96
An approach to endomyocardial biopsy interpretation. J Clin Pathol (2006) 0.95
Blunted myocardial oxygenation response during vasodilator stress in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2013) 0.95
Assessment of intra- and interobserver reproducibility of rest and cold pressor test-stimulated myocardial blood flow with (13)N-ammonia and PET. Eur J Nucl Med Mol Imaging (2007) 0.95
Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: from impaired tubules to impaired carotid and coronary arteries. Clin J Am Soc Nephrol (2008) 0.94
Coronary flow reserve in hypertrophic cardiomyopathy: relation with microvascular dysfunction and pathophysiological characteristics. Neth Heart J (2007) 0.93
Coronary microvascular ischemia in hypertrophic cardiomyopathy - a pixel-wise quantitative cardiovascular magnetic resonance perfusion study. J Cardiovasc Magn Reson (2014) 0.92
Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Kardiol (2005) 0.89
Anatomy and physiology of coronary blood flow. J Nucl Cardiol (2010) 0.88
Diagnostic value of PET-measured heterogeneity in myocardial blood flows during cold pressor testing for the identification of coronary vasomotor dysfunction. J Nucl Cardiol (2007) 0.86
Continuous cardiac troponin I release in Fabry disease. PLoS One (2014) 0.86
The non-invasive documentation of coronary microcirculation impairment: role of transthoracic echocardiography. Cardiovasc Ultrasound (2005) 0.86
Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging (2013) 0.86
Left Ventricular Hypertrophy in Rhesus Macaques (Macaca mulatta) at the California National Primate Research Center (1992-2014). Comp Med (2016) 0.86
The Human Microcirculation: Regulation of Flow and Beyond. Circ Res (2016) 0.86
Mechanisms of Myocardial Ischemia in Hypertrophic Cardiomyopathy: Insights From Wave Intensity Analysis and Magnetic Resonance. J Am Coll Cardiol (2016) 0.84
Present and future of clinical cardiovascular PET imaging in Europe--a position statement by the European Council of Nuclear Cardiology (ECNC). Eur J Nucl Med Mol Imaging (2008) 0.83
Assessment of myocardial perfusion and function with PET and PET/CT. J Nucl Cardiol (2010) 0.83
Quantitative cardiac positron emission tomography: the time is coming! Scientifica (Cairo) (2012) 0.82
The role of nuclear imaging in the failing heart: myocardial blood flow, sympathetic innervation, and future applications. Heart Fail Rev (2011) 0.82
Peripheral vascular endothelial function in patients with hypertrophic cardiomyopathy. Am J Cardiol (2010) 0.82
Diagnostic and clinical perspectives of fusion imaging in cardiology: is the total greater than the sum of its parts? Heart (2005) 0.82
Myocardial flow reserve is influenced by both coronary artery stenosis severity and coronary risk factors in patients with suspected coronary artery disease. Eur J Nucl Med Mol Imaging (2006) 0.81
Prognostic value of intra-left ventricular electromechanical asynchrony in patients with mild hypertrophic cardiomyopathy compared with power athletes. Br J Sports Med (2006) 0.81
Impact of alcohol septal ablation on left anterior descending coronary artery blood flow in hypertrophic obstructive cardiomyopathy. Int J Cardiovasc Imaging (2009) 0.80
Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal. Eur J Nucl Med Mol Imaging (2016) 0.80
Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM). Eur J Nucl Med Mol Imaging (2016) 0.78
Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a (13)NH3 gated PET study. Eur J Nucl Med Mol Imaging (2017) 0.78
Targeting the dominant mechanism of coronary microvascular dysfunction with intracoronary physiology tests. Int J Cardiovasc Imaging (2017) 0.78
Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies. Heart Fail Rev (2017) 0.77
Myocardial perfusion MRI shows impaired perfusion of the mouse hypertrophic left ventricle. Int J Cardiovasc Imaging (2014) 0.77
In hypertrophic cardiomyopathy reduction of relative resting myocardial blood flow is related to late enhancement, T2-signal and LV wall thickness. PLoS One (2012) 0.77
Microvascular ischemia in hypertrophic cardiomyopathy: new insights from high-resolution combined quantification of perfusion and late gadolinium enhancement. J Cardiovasc Magn Reson (2016) 0.77
Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy. Heart Vessels (2006) 0.77
Impaired myocardial microcirculation in the flow-glucose metabolism mismatch regions in revascularized acute myocardial infarction. J Nucl Cardiol (2016) 0.76
The expanding role of epigenetics. Glob Cardiol Sci Pract (2012) 0.76
Regional Stress-Induced Ischemia in Non-fibrotic Hypertrophied Myocardium in Young HCM Patients. Pediatr Cardiol (2015) 0.76
Abnormal T2-STIR magnetic resonance in hypertrophic cardiomyopathy: a marker of advanced disease and electrical myocardial instability. PLoS One (2014) 0.75
Comparison of Outcomes in Patients With Nonobstructive, Labile-Obstructive, and Chronically Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol (2015) 0.75
PET and MRI for the evaluation of regional myocardial perfusion and wall thickening after myocardial infarction. Eur J Nucl Med Mol Imaging (2012) 0.75
Low esophageal mucosal blood flow in patients with nutcracker esophagus. Am J Physiol Gastrointest Liver Physiol (2015) 0.75
Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of Care. Adv Med (2014) 0.75
Echocardiographic predictors of severe heart failure symptoms in hypertrophic cardiomyopathy patients with sinus rhythm. Trials (2008) 0.75
Coronary microcirculation changes in non-ischemic dilated cardiomyopathy identified by novel perfusion CT. Int J Cardiovasc Imaging (2015) 0.75
Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype? Eur Heart J Cardiovasc Imaging (2015) 0.75
Role of left ventricular twist mechanics in cardiomyopathies, dance of the helices. World J Cardiol (2015) 0.75
Findings of Cardiac Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy after 16 Years. J Cardiovasc Ultrasound (2016) 0.75
Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy. Nat Rev Cardiol (2016) 0.75
Tunneled left anterior descending artery in a child with hypertrophic cardiomyopathy. Nat Clin Pract Cardiovasc Med (2008) 0.75
Blood flow, flow reserve, and glucose utilization in viable and nonviable myocardium in patients with ischemic cardiomyopathy. Eur J Nucl Med Mol Imaging (2013) 0.75
Complementary Role of Echocardiography and Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy. Curr Cardiol Rep (2017) 0.75
The Potential of Clinical Phenotyping of Heart Failure With Imaging Biomarkers for Guiding Therapies: A Focused Update. JACC Cardiovasc Imaging (2017) 0.75
Protocol for measuring myocardial blood flow by PET/CT in cats. Eur J Nucl Med Mol Imaging (2008) 0.75
Microvascular function, is there a link to myocardial viability: Is this another piece to the puzzle? J Nucl Cardiol (2016) 0.75
3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy. Int J Cardiovasc Imaging (2017) 0.75
Coronary vasomotor function assessed by positron emission tomography. Eur J Nucl Med Mol Imaging (2009) 0.75
Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines. J Mol Cell Cardiol (2017) 0.75
Microvascular dysfunction in nonfailing arrhythmogenic right ventricular cardiomyopathy. Eur J Nucl Med Mol Imaging (2011) 0.75
Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy. Heart Fail Rev (2017) 0.75
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86
Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J (2006) 5.79
Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med (2003) 5.17
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation (2006) 3.82
Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation (2012) 2.78
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol (2005) 2.43
Myocardial oxygenation in coronary artery disease: insights from blood oxygen level-dependent magnetic resonance imaging at 3 tesla. J Am Coll Cardiol (2012) 2.38
Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol (2007) 2.22
Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes. Catheter Cardiovasc Interv (2009) 2.07
Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation (2011) 2.04
Functional changes in coronary microcirculation after valve replacement in patients with aortic stenosis. Circulation (2003) 1.91
Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur Heart J (2011) 1.82
Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol (2010) 1.80
Myocardial blood flow measurement by PET: technical aspects and clinical applications. J Nucl Med (2005) 1.74
Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol (2006) 1.66
The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol (2009) 1.66
Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol (2006) 1.65
Relationship between regional myocardial oxygenation and perfusion in patients with coronary artery disease: insights from cardiovascular magnetic resonance and positron emission tomography. Circ Cardiovasc Imaging (2009) 1.61
Systemic inhibition of nitric oxide synthase unmasks neural constraint of maximal myocardial blood flow in humans. Circulation (2004) 1.59
Absolute quantification of myocardial blood flow with H(2)(15)O and 3-dimensional PET: an experimental validation. J Nucl Med (2002) 1.57
Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med (2006) 1.56
Occurrence of regional left ventricular dysfunction in patients undergoing standard and biofeedback dialysis. Am J Kidney Dis (2006) 1.49
Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol (2009) 1.48
Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol (2007) 1.47
Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy. Am J Cardiol (2010) 1.46
Anatomic versus physiologic assessment of coronary artery disease. Role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making. J Am Coll Cardiol (2013) 1.44
Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy. Eur J Nucl Med Mol Imaging (2015) 1.41
Comparison of myocardial blood flow and coronary flow reserve during dobutamine and adenosine stress: Implications for pharmacologic stress testing in coronary artery disease. J Nucl Cardiol (2006) 1.39
Patent foramen ovale closure and brain ischaemic lesions. Heart (2013) 1.39
[Management of refractory symptoms in hypertrophic cardiomyopathy with restrictive pathophysiology: novel perspectives for ranolazine]. G Ital Cardiol (Rome) (2012) 1.38
Mechanisms of coronary microcirculatory dysfunction in patients with aortic stenosis and angiographically normal coronary arteries. Circulation (2002) 1.36
Coronary microvascular dysfunction: an update. Eur Heart J (2013) 1.28
Program of cell survival underlying human and experimental hibernating myocardium. Circ Res (2004) 1.27
Coronary microvascular resistance: methods for its quantification in humans. Basic Res Cardiol (2009) 1.26
Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur Heart J (2009) 1.26
Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging (2010) 1.19
Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2002) 1.18
The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. J Physiol (2008) 1.14
Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol (2006) 1.13
The dilemma of left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy: do patients with gradients really deserve prophylactic defibrillators? Eur Heart J (2006) 1.13
Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2003) 1.13
Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J (2009) 1.12
Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. Eur Heart J (2011) 1.11
Respiratory gating of cardiac PET data in list-mode acquisition. Eur J Nucl Med Mol Imaging (2006) 1.10
Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol (2006) 1.10
Evaluation of the microcirculation in hypertension and cardiovascular disease. Eur Heart J (2007) 1.09
Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J (2012) 1.08
Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol (2007) 1.07
Can silent brain lesions be a target to guide anticoagulation treatment in patients with low-risk atrial fibrillation to reduce cognitive impairment? J Am Coll Cardiol (2014) 1.06
Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/computed tomography angiography. J Am Coll Cardiol (2010) 1.05
Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol (2011) 1.03
A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown) (2006) 1.01
Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes (2002) 1.00
The coronary circulation and blood flow in left ventricular hypertrophy. J Mol Cell Cardiol (2011) 0.99
Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging (2013) 0.97
Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovasc Ultrasound (2010) 0.96
Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in tuscany. Am J Cardiol (2003) 0.95
Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy. J Cardiovasc Transl Res (2009) 0.95
Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace (2010) 0.94
Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome. Circulation (2004) 0.93
[Percutaneous coronary interventions. Guidelines of the European Society of Cardiology-ESC]. Kardiol Pol (2005) 0.93
Determinants of echocardiographic left atrial volume: implications for normalcy. Eur J Echocardiogr (2011) 0.93
Left ventricular apical ballooning syndrome as a novel cause of acute mitral regurgitation. J Am Coll Cardiol (2007) 0.92
Assessment of myocardial ischaemia and viability: role of positron emission tomography. Eur Heart J (2010) 0.91
Absolute blood flow and oxygen consumption in stunned myocardium in patients with coronary artery disease. J Am Coll Cardiol (2002) 0.91
Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. J Nucl Med (2008) 0.91
Effectiveness of a multidisciplinary chest pain unit for the assessment of coronary syndromes and risk stratification in the Florence area. Am Heart J (2002) 0.91
Quantification of subendocardial and subepicardial blood flow using 15O-labeled water and PET: experimental validation. J Nucl Med (2006) 0.91
Effect of repeated episodes of reversible myocardial ischemia on myocardial blood flow and function in humans. Am J Physiol Heart Circ Physiol (2002) 0.90
Tetrahydrobiopterin restores impaired coronary microvascular dysfunction in hypercholesterolaemia. Eur J Nucl Med Mol Imaging (2004) 0.90
Myocardial beta-adrenoceptor down-regulation early after infarction is associated with long-term incidence of congestive heart failure. Eur Heart J (2010) 0.90
Detection and quantification of large-vessel inflammation with 11C-(R)-PK11195 PET/CT. J Nucl Med (2010) 0.90
123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol (2009) 0.89
'End-stage' hypertrophic cardiomyopathy: from mystery to model. Nat Clin Pract Cardiovasc Med (2007) 0.89
[Evaluation of the appropriateness of prescribing echocardiography]. Ital Heart J Suppl (2002) 0.89
Myocardial beta-adrenoceptor density one month after acute myocardial infarction predicts left ventricular volumes at six months. J Am Coll Cardiol (2002) 0.89
Early results of sarcomeric gene screening from the Egyptian National BA-HCM Program. J Cardiovasc Transl Res (2012) 0.89
Is there evidence supporting coronary revascularization in patients with left ventricular systolic dysfunction? Circ J (2010) 0.88
Metabolomic fingerprint of heart failure in humans: a nuclear magnetic resonance spectroscopy analysis. Int J Cardiol (2013) 0.88
MR Imaging in Hypertrophic Cardiomyopathy: From Magnet to Bedside. Radiology (2014) 0.88
Measurement of ventricular volumes and function: a comparison of gated PET and cardiovascular magnetic resonance. J Nucl Med (2002) 0.87
Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition. Int J Cardiol (2008) 0.86
Early discharge after acute myocardial infarction in the current clinical practice. Community data from the AMI-Florence Registry, Italy. Int J Cardiol (2006) 0.86
Regional myocardial blood flow and glucose utilization during fasting and physiological hyperinsulinemia in humans. Am J Physiol Endocrinol Metab (2002) 0.86
Distal extremity pain as a presenting feature of Fabry's disease. Arthritis Care Res (Hoboken) (2010) 0.86
Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction. Am Heart J (2006) 0.86
Myocardial pre-synaptic sympathetic function correlates with glucose uptake in the failing human heart. Eur J Nucl Med Mol Imaging (2007) 0.85
[Appropriateness of prescription of exercise stress test, echocardiography, Holter monitoring and vascular echography]. G Ital Cardiol (Rome) (2007) 0.85
Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: a retrospective database analysis. BMJ Open (2012) 0.85
Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol (2007) 0.85
Perindopril and indapamide reverse coronary microvascular remodelling and improve flow in arterial hypertension. J Hypertens (2011) 0.84
The Italian Registry for hypertrophic cardiomyopathy: a nationwide survey. Am Heart J (2005) 0.84
Assessment of the long-term reproducibility of baseline and dobutamine-induced myocardial blood flow in patients with stable coronary artery disease. J Nucl Med (2005) 0.84